SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-138249
Filing Date
2024-05-14
Accepted
2024-05-14 16:16:08
Documents
15
Period of Report
2024-05-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d798777d8k.htm   iXBRL 8-K 24870
2 EX-99.1 d798777dex991.htm EX-99.1 47107
6 GRAPHIC g798777g0514010601169.jpg GRAPHIC 2585
  Complete submission text file 0001193125-24-138249.txt   209504

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA avir-20240514.xsd EX-101.SCH 2860
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE avir-20240514_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE avir-20240514_pre.xml EX-101.PRE 11268
18 EXTRACTED XBRL INSTANCE DOCUMENT d798777d8k_htm.xml XML 3638
Mailing Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110
Business Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110 857-204-8109
Atea Pharmaceuticals, Inc. (Filer) CIK: 0001593899 (see all company filings)

IRS No.: 460574869 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39661 | Film No.: 24944581
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)